Davis Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$109 Hold
6
– – ﹤0.01% 1011
2026
Q2
$108 Buy
+6
New +$113 ﹤0.01% 1045

Other funds holding SRPT

Davis Capital Management's SRPT Position: Q3 2026 in Review

Davis Capital Management held its Sarepta Therapeutics (SRPT) position steady in Q3 2026 at 6 shares worth $109. The position accounts for ﹤0.01% of the portfolio, ranked #1011.

Davis Capital Management first reported a position in SRPT in Q2 2026 and has held it in 2 quarters since. 305 funds tracked by Wall St. Rank hold SRPT as of Q3 2026.

  • Davis Capital Management held 6 shares of Sarepta Therapeutics worth $109 as of Q3 2026.
  • Davis Capital Management left its Sarepta Therapeutics share count unchanged in Q3 2026.
  • Sarepta Therapeutics made up ﹤0.01% of Davis Capital Management's portfolio in Q3 2026, its #1011 holding.
  • Davis Capital Management first reported a position in Sarepta Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • 305 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2026.

Based on Davis Capital Management's 13F filing for Q3 2026, filed 8 Oct 2026.